These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 20853607)
1. [Results of hematopoietic cell transplantation in the first complete remission in children with acute myeloid leukemia from an intermediate risk group]. SDyshlevaia ZM; Skorobogatova EV; Maschan MA; Shipitsyna IP; Skvortsova IuV; Trakhtman PE; Balashov DN; Pashko IuV; Kurnikova EE; Suntsova EV; Goronkova OV; Solopova GG; Baĭdil'dina DD; Kalinina II; Khachatrian LA; Shneĭder MM; Maschan AA Ter Arkh; 2010; 82(7):34-40. PubMed ID: 20853607 [TBL] [Abstract][Full Text] [Related]
2. [Role of antithymocyte globulin in reducing the incidence of complications after allogeneic hemopoietic cell transplantation]. Zalialov IuR; Ganapiev AA; Golubovskaia IK; Afanas'ev BV Ter Arkh; 2010; 82(8):53-6. PubMed ID: 20873247 [TBL] [Abstract][Full Text] [Related]
3. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465 [TBL] [Abstract][Full Text] [Related]
4. [Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission]. Wang HH; Feng SZ; Wang M; Wei JL; Jiang EL; Zhang L; Huang Y; Zhou SY; Liu QG; Qiu LG; Han MZ; Yan WW Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):389-92. PubMed ID: 15355688 [TBL] [Abstract][Full Text] [Related]
5. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia. Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650 [TBL] [Abstract][Full Text] [Related]
6. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801 [TBL] [Abstract][Full Text] [Related]
7. Autologous stem cell transplantation in acute myeloid leukemia. Factors influencing outcome. A 13 year single institution experience. Martins C; Lacerda JF; Lourenço F; Carmo JA; Lacerda JM Acta Med Port; 2005; 18(5):329-37. PubMed ID: 16611537 [TBL] [Abstract][Full Text] [Related]
8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
9. Impact of conditioning regimen in allogeneic hematopoetic stem cell transplantation for children with acute myelogenous leukemia beyond first complete remission: a pediatric blood and marrow transplant consortium (PBMTC) study. Sisler IY; Koehler E; Koyama T; Domm JA; Ryan R; Levine JE; Pulsipher MA; Haut PR; Schultz KR; Taylor DS; Frangoul HA Biol Blood Marrow Transplant; 2009 Dec; 15(12):1620-7. PubMed ID: 19896086 [TBL] [Abstract][Full Text] [Related]
10. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy. Ortega JJ; Díaz de Heredia C; Olivé T; Bastida P; Llort A; Armadans L; Torrabadella M; Massuet L Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268 [TBL] [Abstract][Full Text] [Related]
11. [Effects of allogeneic hematopoietic stem cell transplantation with very-high-dose conditioning regimen for refractory leukemia]. Liu QF; Sun J; Xu D; Zhang Y; Fan ZP; Wei YQ; Meng FY; Zhou SY Di Yi Jun Yi Da Xue Xue Bao; 2004 Oct; 24(10):1117-9. PubMed ID: 15485779 [TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine. Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990 [TBL] [Abstract][Full Text] [Related]
13. [Allogenic transplantation of hematopoietic stem cells in the treatment of children with high-risk acute leukemia]. Starý J; Kobylka P; Sedlácek P; Komrska V; Vávra V; Syrůcková Z; Smísek P; Hrubá A; Korínková P; Matĕjková E; Cukrová V; Dolezalová L; Loudová M; Sejkorová J; Kvĕch J Cas Lek Cesk; 1998 Jun; 137(12):363-7. PubMed ID: 9721472 [TBL] [Abstract][Full Text] [Related]
14. Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond--the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation. Gorin NC; Labopin M; Boiron JM; Theorin N; Littlewood T; Slavin S; Greinix H; Cahn JY; Alessandrino EP; Rambaldi A; Nagler A; Polge E; Rocha V; J Clin Oncol; 2006 Aug; 24(24):3959-66. PubMed ID: 16880451 [TBL] [Abstract][Full Text] [Related]
15. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning. Grigg AP; Gibson J; Bardy PG; Reynolds J; Shuttleworth P; Koelmeyer RL; Szer J; Roberts AW; To LB; Kennedy G; Bradstock KF Biol Blood Marrow Transplant; 2007 May; 13(5):560-7. PubMed ID: 17448915 [TBL] [Abstract][Full Text] [Related]
16. The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy. Cook G; Clark RE; Crawley C; Mackinnon S; Russell N; Thomson K; Pearce RM; Towlson K; Marks DI Biol Blood Marrow Transplant; 2006 Mar; 12(3):293-300. PubMed ID: 16503498 [TBL] [Abstract][Full Text] [Related]
17. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method. Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794 [TBL] [Abstract][Full Text] [Related]
18. High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation. Cesaro S; Meloni G; Messina C; Pillon M; Proglia A; Lanino E; Caniggia M; Bagnulo S; Pession A; Locatelli F; Bone Marrow Transplant; 2001 Jul; 28(2):131-6. PubMed ID: 11509930 [TBL] [Abstract][Full Text] [Related]
19. Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission. Fouillard L; Labopin M; Gratwohl A; Gluckman E; Frassoni F; Beelen DW; Willemze R; Montserrat E; Blaise D; Atienza AI; Sierra J; Santos M; Gorin NC; Rocha V; Haematologica; 2008 Jun; 93(6):834-41. PubMed ID: 18469352 [TBL] [Abstract][Full Text] [Related]
20. Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen. Maruyama D; Fukuda T; Kato R; Yamasaki S; Usui E; Morita-Hoshi Y; Kim SW; Mori S; Heike Y; Makimoto A; Tajima K; Tanosaki R; Tobinai K; Takaue Y Biol Blood Marrow Transplant; 2007 Aug; 13(8):932-41. PubMed ID: 17640597 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]